SCHEMBL4737084

SCHEMBL4737084

Oc1cccc(Nc2nccc(-c3cccc(C(F)(F)F)c3)n2)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 6/20 0.62
▸ CLK1 P49759 1/20 0.62
▸ CLK2 P49760 1/20 0.62
▸ DYRK1A Q13627 1/20 0.62
▸ CLK4 Q9HAZ1 1/20 0.62
▸ DYRK1B Q9Y463 1/20 0.62
▸ AURKA O14965 3/20 0.58
▸ MTOR P42345 1/20 0.58
▸ SMG1 Q96Q15 1/20 0.58
▸ PLK1 P53350 3/20 0.56
▸ KMO O15229 1/20 0.53
▸ CDK2 P24941 4/20 0.53
▸ CDK4 P11802 1/20 0.53
▸ GSK3B P49841 3/20 0.52
▸ SRC P12931 1/20 0.52
▸ ZAP70 P43403 1/20 0.52
▸ CCNT1 O60563 1/20 0.52
▸ CDK1 P06493 1/20 0.52
▸ CCNB1 P14635 1/20 0.52
▸ CCNA2 P20248 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27115596 0.95 SYK (0.65) SYKCLK1CLK2DYRK1ACLK4
SCHEMBL4738297 0.89 PLK1 (0.68) SYKCLK1CLK2DYRK1ACLK4
SCHEMBL4737537 0.87 SYK (0.67) SYKPLK1CDK2CDK4GSK3B
SCHEMBL27116471 0.87 CLK1 (0.66) CLK1CLK2DYRK1ACLK4DYRK1B
SCHEMBL30847409 0.87 CLK1 (0.66) SYKCLK1CLK2DYRK1ACLK4
SCHEMBL27110252 0.87 CLK1 (0.66) SYKCLK1CLK2DYRK1ACLK4
SCHEMBL4736449 0.87 SYK (0.60) SYKCLK1CLK2DYRK1ACLK4
SCHEMBL2944816 0.85 CLK1 (0.60) SYKCLK1CLK2DYRK1ACLK4
SCHEMBL15533886 0.85 CLK1 (0.67) SYKCLK1CLK2DYRK1ACLK4
SCHEMBL25336406 0.83 CAMK2D (0.69) SYKCLK1CLK2DYRK1ACLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080153822-A1 Methods of treating pain INGENIUM PHARMACEUTICALS GMBH (DE) 2008-06-26 — — US claimed
WO-2008065155-A1 CDK INHIBITORS FOR TREATING PAIN INGENIUM PHARMACEUTICALS GMBH (DE) 2008-06-05 — — WO claimed
US-20070021419-A1 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors CYCLACEL LIMITED (GB) 2007-01-25 — — US claimed
JP-2007500179-A — — 2007-01-11 — — JP claimed
CN-1860104-A 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors CYCLACEL LTD (GB) 2006-11-08 — — CN claimed
EP-1648875-A1 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS Cyclacel Limited (GB) 2006-04-26 — — EP claimed
WO-2005012262-A1 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS CYCLACEL LIMITED (GB) 2005-02-10 — — WO claimed
US-20080153822-A1 Methods of treating pain INGENIUM PHARMACEUTICALS GMBH (DE) 2008-06-26 — — US disclosed
US-20080153822-A1 Methods of treating pain INGENIUM PHARMACEUTICALS GMBH (DE) 2008-06-26 — — US disclosed
US-20080153822-A1 Methods of treating pain INGENIUM PHARMACEUTICALS GMBH (DE) 2008-06-26 — — US disclosed
WO-2008065155-A1 CDK INHIBITORS FOR TREATING PAIN INGENIUM PHARMACEUTICALS GMBH (DE) 2008-06-05 — — WO disclosed
US-20070021419-A1 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors CYCLACEL LIMITED (GB) 2007-01-25 — — US disclosed
US-20070021419-A1 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors CYCLACEL LIMITED (GB) 2007-01-25 — — US disclosed
US-20070021419-A1 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors CYCLACEL LIMITED (GB) 2007-01-25 — — US disclosed
CN-1860104-A 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors CYCLACEL LTD (GB) 2006-11-08 — — CN disclosed
EP-1648875-A1 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS Cyclacel Limited (GB) 2006-04-26 — — EP disclosed
WO-2005012262-A1 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS CYCLACEL LIMITED (GB) 2005-02-10 — — WO disclosed
WO-2005012262-A1 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS CYCLACEL LIMITED (GB) 2005-02-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021419-A1 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors GRK3, NCOR1, GRM3 SYK 1865/4885CLK1 1830/4885CLK2 1318/4885
US-20080153822-A1 Methods of treating pain OPRL1, ACHE, OPRK1 SYK 1957/4885CLK1 4199/4885CLK2 3473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback